Anti-Spike protein [MR17 ]

Absolute Antibody

Anti-Spike protein [MR17 ]

9

This antibody binds the receptor binding domain (RBD) of the SARS-CoV-2.

Wild type MR17 had a modest neutralization activity. ELISA was used to screen the libraries to identify specific RBD binders. Neutralization activity of the sybody was checked by pre-incubating pseudoviral particles with different concentrations of sybody before infection of VeroE6-hACE2 cells. The rate of infection was then measured by fluorescence-activated cell sorting (FACS). IC50 value of wild type MR17 was determined to be 12.32 microg m/L. This sybody is a K99Y mutant version of wild typr MR17. It is seen that the single mutation increased the binding affinity by 1.5 fold and decreased the off-rate by 2.8 fold. Overall neutralization activity was increased 24 fold after the mutation was introduced, with an IC50 value of 0.50 microg m/L. The binding kinetics between sybodies and the RBD was assessed using bio-layer interferometry (Li et al., 2020).

Flow Cytometry, ELISA, Neutralisation/Blocking, Other Application

Research Use Only

Monoclonal

MR17

S

surface glycoprotein

GU280_gp02; spike glycoprotein; surface glycoprotein

Camel

Spike glycoprotein

This chimeric camelid antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques.

Virus

-20°C,2°C to 8°C

12352203